VivoSeq
Other

Immune Checkpoint Inhibition

0

Pipeline Programs↗

7

Active Trials↗

0

Companies Involved↗

Immune Checkpoint Inhibition is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

9/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

11

clinical trials

Recruiting4 · 36%
Completed2 · 18%
Active, not recruiting2 · 18%
Unknown status1 · 9%
Terminated1 · 9%
Not yet recruiting1 · 9%

Clinical Trials

Trial Activity

11 trials

Treatment of Cancer With Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound Histotripsy
Recruiting·UUMC Utrecht·Phase 1·NCT06524570·24 enrolled
Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer
Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT03026140·353 enrolled
FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition
Recruiting·UUniversity Hospital Tuebingen·Phase 1·NCT05937295·20 enrolled
Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases
Recruiting·—·Phase 1·NCT05481658·100 enrolled
Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
Active, not recruiting·—·Phase 1·NCT04620603·5 enrolled
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06754501·4 enrolled
Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC)
Not yet recruiting·UUniversity of Florida·Phase 2·NCT07487805·80 enrolled
Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition
Completed·WWake Forest University Health Sciences·Phase 2·NCT04454489·21 enrolled
Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition
Completed·UUniversity of Erlangen-Nürnberg Medical School·N/A·NCT03453892·150 enrolled
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT04610658·9 enrolled
REduced Frequency ImmuNE Checkpoint Inhibition in Cancers
Unknown status·UUniversity College, London·Phase 2·NCT04913025·160 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)